Mesoblast, Melbourne, Australia, announced that it has received
Australia’s first institutional ethics-committee approval for a
human trial evaluating the use of an adult stem-cell product to
prevent knee osteoarthritis (OA) in patients who have had surgery
to repair a damaged anterior cruciate ligament (ACL). The company
will use its own proprietary stem-cell product, RepliCart, on 12
patients, compared to a matched placebo-controlled group of 12.